Orthopediatrics (KIDS) Research & Development (2016 - 2026)

Orthopediatrics (KIDS) has reported Research & Development for 11 consecutive years, with $21.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 11.47% year-over-year to $21.3 million in Q2 2026; TTM through Jun 2026 was $76.8 million, a 10.99% increase from a year earlier, with the FY2025 full-year figure at $72.7 million, up 13.11% from the prior year.
• Research & Development was $21.3 million for Q2 2026 at Orthopediatrics, up from $18.5 million in the prior quarter.
• Over five years, Research & Development peaked at $21.3 million in Q2 2026 and troughed at $9.8 million in Q1 2022.
• A 5-year average of $15.3 million and a median of $15.4 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development increased 6.79% in 2023 and soared 31.13% in 2024, its largest moves.
• Over 5 years, Research & Development stood at $12.0 million in 2022, then increased by 6.79% to $12.8 million in 2023, then soared by 31.13% to $16.8 million in 2024, then advanced by 9.62% to $18.4 million in 2025, then climbed by 15.73% to $21.3 million in 2026.
• The last three Research & Development figures came in at $21.3 million (Q2 2026), $18.5 million (Q1 2026), and $18.4 million (Q4 2025), per Business Quant data.